HZ:CSEHertz Energy Inc. Analysis
Data as of 2026-05-29 - not real-time
$34.44
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
MarineMax (HZ) is trading at $34.44, comfortably above its 20‑day SMA of $32.90 and its 50‑day SMA of $29.89, indicating a short‑term uptrend that aligns with the 200‑day SMA of $27.11. The RSI of 60.3 reinforces moderate momentum without sign of overbought conditions. A bullish MACD crossover (line $1.40 above signal $1.34) adds further technical support for upside. Beta of 2.05 and a 30‑day volatility of 53% signal pronounced price swings, underscoring the need for caution. Volume is trending lower, suggesting waning buying pressure despite the bullish signals. The stock sits near the upper end of its 52‑week range ($36.25 resistance) and above the identified support at $27.50. Overall, the technical landscape points to a continued bullish bias in the near term.
Fundamentally, the company posted a 16.5% revenue decline and a negative profit margin, reflecting headwinds in the consumer‑cyclical boat market. Operating cash flow remains positive at $218 M, and free cash flow of $127 M provides a cushion despite a high debt‑to‑equity ratio of 128%. The forward EPS of $1.62 translates to a forward P/E of 21.3, while the price‑to‑book of 0.81 suggests the market values the firm below its book equity. A discounted cash flow model yields a fair value of $29.9, implying the current price carries a modest premium. No dividend is paid, eliminating dividend‑based income considerations. Analyst consensus leans toward a strong‑buy with a median target of $35, indicating modest upside potential. Given the mix of valuation compression, cash generation, and sector sensitivity, the stock appears fairly valued with a blend of growth and value characteristics.
Fundamentally, the company posted a 16.5% revenue decline and a negative profit margin, reflecting headwinds in the consumer‑cyclical boat market. Operating cash flow remains positive at $218 M, and free cash flow of $127 M provides a cushion despite a high debt‑to‑equity ratio of 128%. The forward EPS of $1.62 translates to a forward P/E of 21.3, while the price‑to‑book of 0.81 suggests the market values the firm below its book equity. A discounted cash flow model yields a fair value of $29.9, implying the current price carries a modest premium. No dividend is paid, eliminating dividend‑based income considerations. Analyst consensus leans toward a strong‑buy with a median target of $35, indicating modest upside potential. Given the mix of valuation compression, cash generation, and sector sensitivity, the stock appears fairly valued with a blend of growth and value characteristics.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- bullish SMA and MACD alignment
- price above key moving averages
- high volatility and decreasing volume
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- forward EPS improvement
- fair valuation with DCF upside
- positive operating cash flow
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- elevated debt load
- declining revenue trend
- potential sector recovery
Key Metrics & Analysis
Financial Health
Revenue Growth-16.50%
Profit Margin-2.83%
P/E Ratio21.3
ROE-6.46%
ROA1.14%
Debt/Equity127.78
P/B Ratio0.8
Op. Cash Flow$218.7M
Free Cash Flow$126.6M
Technical Analysis
TrendBullish
RSI60.3
Support$27.50
Resistance$36.25
MA 20$32.90
MA 50$29.89
MA 200$27.11
MACDBullish
VolumeDecreasing
Fear & Greed Index94.07
Valuation
Fair Value$29.92
Target Price$35.29
Upside/Downside2.46%
GradeFair
TypeBlend
Risk Assessment
Beta2.05
Volatility53.44%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.